Clinical recommendation	Evidence rating	Comments
Patients with PMR should be treated with the minimum effective dose of oral glucocorticoids with individualized duration.14,19,22	C	Expert opinion
Early addition of methotrexate to glucocorticoid therapy should be considered in patients with PMR who are at high risk of relapse or glucocorticoid-related adverse events.7,8,19	A	Consistent results from multiple randomized controlled trials
Intramuscular methylprednisolone every three weeks should be considered as an alternative to oral glucocorticoids in patients at high risk of adverse effects from glucocorticoids.8,19	B	A single small, high-quality randomized controlled trial
Dose-tapering schedules for patients with PMR should be individualized based on monitoring of disease activity, laboratory markers, and adverse events.19	C	Expert opinion in the absence of clinical trials
In patients with newly diagnosed GCA, noninvasive vascular imaging (i.e., magnetic resonance imaging or computed tomography angiography) of the neck, chest, abdomen, and pelvis should be performed to evaluate for large vessel involvement.20	C	Lower-quality evidence and consensus guidelines
To improve chances of successful remission, patients with newly diagnosed GCA should be treated with high-dose oral glucocorticoids and subcutaneous interleukin-6 antagonist tocilizumab (Actemra) over glucocorticoids alone.8,20,38,39	A	Two high-quality randomized controlled trials with consistent results and consensus guidelines
Long-term monitoring is recommended for patients with GCA who are in clinical remission.20	C	Evidence showing that monitoring is low risk and there is potential for harm from not monitoring; consensus guidelines